Bolt Biotherapeutics (NASDAQ:BOLT) Issues Earnings Results, Meets Expectations

Bolt Biotherapeutics (NASDAQ:BOLT) posted its earnings results on Monday. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38), Zacks reports. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Bolt Biotherapeutics Stock Down 4.0 %

Shares of NASDAQ BOLT opened at $0.42 on Wednesday. The firm’s 50 day moving average price is $0.47 and its 200 day moving average price is $0.56. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The firm has a market cap of $16.07 million, a P/E ratio of -0.25 and a beta of 0.94. Bolt Biotherapeutics has a 1 year low of $0.38 and a 1 year high of $1.56.

Wall Street Analyst Weigh In

BOLT has been the subject of several research reports. HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Tuesday. Stifel Nicolaus reduced their price objective on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $1.13.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.